Our Pipeline
We never lose sight of why our work matters – the potential to impact the lives of patients is important to everyone at Sana. We are advancing a number of innovative drug candidates with the goal of disrupting the possible for patients across a diverse set of diseases.
Expanded Access Policy
Sana is committed to developing safe and effective engineered cells as medicines, which involves evaluation in clinical trials followed by submission of the trial results to regulatory agencies, such as the U.S. Food and Drug Administration (FDA). These investigational therapies have not yet been approved by regulatory authorities. “Expanded access” refers to the use of an unapproved investigational therapy outside of a clinical trial for the potential treatment of a serious or immediately life-threatening condition. We recognize that people living with the diseases we are studying may be interested in accessing our therapies prior to regulatory approval. We want to facilitate a comprehensive understanding of the safety, tolerability, and efficacy of our investigational therapies, which is why monitored participation in clinical trials is the only way to access our investigational therapies.
If you have additional questions, please speak with your physician.
Our therapies are investigational and have not been approved by the FDA or any other regulatory agency.
